Atrium Therapeutics grants new hire stock options for 7,000 shares at USD 11.76 exercise price
RNA•Vesting terms and inducement plan
The options vest 25% after one year, then monthly over 36 months; 3,500 restricted stock units vest 25% after one year, then annually over three years.
The inducement plan was adopted by the board in April 2026; awards were granted outside stockholder-approved equity plans.
Equity awards granted to one new hire
Atrium Therapeutics granted equity awards on July 20, 2026 under its 2026 Employment Inducement Incentive Award Plan for one new non-executive hire.
The package totals 7,000 non-qualified stock options priced at USD 11.76 per share, based on the Nasdaq close on the grant date.
